Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases

Core Insights - Zealand Pharma and OTR Therapeutics have entered a multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases [2][3] - The collaboration aims to leverage Zealand Pharma's expertise in obesity and metabolic health alongside OTR Therapeutics' proprietary R&D platform to create transformative treatment options [3][4] Company Overview - Zealand Pharma is a biotechnology company focused on advancing medicines for obesity and metabolic health, with over 25 years of peptide R&D expertise [7][8] - OTR Therapeutics, launched in March 2025, is dedicated to transforming early-stage innovations into impactful therapies for critical diseases, with a focus on oncology, immunology, inflammation, and cardiometabolic diseases [10] Collaboration Details - The agreement involves co-discovery and co-development of innovative therapies for multiple targets in metabolic diseases, with OTR leading research and preclinical development while Zealand Pharma handles clinical development and commercialization [5][6] - OTR Therapeutics will receive an initial upfront payment of USD 20 million, potentially increasing to USD 30 million, with total consideration up to approximately USD 2.5 billion, primarily from commercial milestones [6][7]